27623277|t|Patient Preferences in Treatment Choices for Early-Stage Lung Cancer
27623277|a|Decision-making for lung cancer treatment can be complex because it involves both provider recommendations based on the patient's clinical condition and patient preferences. This study describes the relative importance of several considerations in lung cancer treatment from the patient's perspective. A conjoint preference experiment began by asking respondents to imagine that they had just been diagnosed with lung cancer. Respondents then chose among procedures that differed regarding treatment modalities, the potential for treatment -related complications, the likelihood of recurrence, provider case volume, and distance needed to travel for treatment. Conjoint analysis derived relative weights for these attributes. A total of 225 responses were analyzed. Respondents were most willing to accept minimally invasive operations for treatment of their hypothetical lung cancer, followed by stereotactic body radiation therapy (SBRT); they were least willing to accept thoracotomy. Treatment type and risk of recurrence were the most important attributes from the conjoint experiment (each with a relative weight of 0.23), followed by provider volume (relative weight of 0.21), risk of major complications (relative weight of 0.18), and distance needed to travel for treatment (relative weight of 0.15). Procedural and treatment preferences did not vary with demographics, self-reported health status, or familiarity with the procedures. Survey respondents preferred minimally invasive operations over SBRT or thoracotomy for treatment of early-stage non-small cell lung cancer. Treatment modality and risk of cancer recurrence were the most important factors associated with treatment preferences. Provider experience outweighed the potential need to travel for lung cancer treatment.
27623277	0	19	Patient Preferences	T080	C0376409
27623277	23	32	Treatment	T061	C0087111
27623277	33	40	Choices	T052	C1707391
27623277	45	56	Early-Stage	T079	C2363430
27623277	57	68	Lung Cancer	T191	C0242379
27623277	69	84	Decision-making	T041	C0011109
27623277	89	100	lung cancer	T191	C0242379
27623277	101	110	treatment	T061	C0087111
27623277	118	125	complex	T080	C0439855
27623277	151	159	provider	T097	C0031831
27623277	160	175	recommendations	T078	C0034866
27623277	189	198	patient's	T101	C0030705
27623277	199	207	clinical	T080	C0205210
27623277	208	217	condition	T080	C0348080
27623277	222	241	patient preferences	T080	C0376409
27623277	248	253	study	T062	C2603343
27623277	299	313	considerations	T033	C0518609
27623277	317	328	lung cancer	T191	C0242379
27623277	329	338	treatment	T061	C0087111
27623277	348	357	patient's	T101	C0030705
27623277	358	369	perspective	T041	C0871010
27623277	373	403	conjoint preference experiment	T062	C0681814
27623277	420	431	respondents	T098	C0282122
27623277	467	476	diagnosed	T033	C0011900
27623277	482	493	lung cancer	T191	C0242379
27623277	495	506	Respondents	T098	C0282122
27623277	512	517	chose	T052	C1707391
27623277	524	534	procedures	T061	C0087111
27623277	559	568	treatment	T061	C0087111
27623277	569	579	modalities	T077	C3889585
27623277	599	608	treatment	T061	C0087111
27623277	618	631	complications	T046	C0009566
27623277	637	647	likelihood	T081	C0033204
27623277	651	661	recurrence	T067	C0034897
27623277	663	671	provider	T097	C0031831
27623277	672	676	case	T169	C0868928
27623277	677	683	volume	T081	C0449468
27623277	689	697	distance	T081	C0012751
27623277	698	704	needed	T169	C1514873
27623277	708	714	travel	T056	C0040802
27623277	719	728	treatment	T061	C0087111
27623277	730	747	Conjoint analysis	T062	C0681814
27623277	783	793	attributes	T080	C1521970
27623277	810	819	responses	T170	C1706817
27623277	825	833	analyzed	T062	C0936012
27623277	835	846	Respondents	T098	C0282122
27623277	875	884	minimally	T080	C0547040
27623277	885	904	invasive operations	T061	C4048276
27623277	909	918	treatment	T061	C0087111
27623277	941	952	lung cancer	T191	C0242379
27623277	966	1001	stereotactic body radiation therapy	T061	C3896609
27623277	1003	1007	SBRT	T061	C3896609
27623277	1044	1055	thoracotomy	T061	C0039991
27623277	1057	1066	Treatment	T061	C0087111
27623277	1076	1094	risk of recurrence	T081	C2986492
27623277	1119	1129	attributes	T080	C1521970
27623277	1139	1158	conjoint experiment	T062	C0681814
27623277	1210	1218	provider	T097	C0031831
27623277	1219	1225	volume	T081	C0449468
27623277	1253	1257	risk	T078	C0035647
27623277	1267	1280	complications	T046	C0009566
27623277	1312	1320	distance	T081	C0012751
27623277	1321	1327	needed	T169	C1514873
27623277	1331	1337	travel	T056	C0040802
27623277	1342	1351	treatment	T061	C0087111
27623277	1379	1389	Procedural	T061	C0087111
27623277	1394	1403	treatment	T061	C0087111
27623277	1404	1415	preferences	T078	C0558295
27623277	1434	1446	demographics	T080	C1521970
27623277	1448	1461	self-reported	T062	C2700446
27623277	1462	1475	health status	T080	C0018759
27623277	1480	1491	familiarity	T041	C0600269
27623277	1501	1511	procedures	T061	C0087111
27623277	1513	1519	Survey	T170	C0038951
27623277	1520	1531	respondents	T098	C0282122
27623277	1542	1551	minimally	T080	C0547040
27623277	1552	1571	invasive operations	T061	C4048276
27623277	1577	1581	SBRT	T061	C3896609
27623277	1585	1596	thoracotomy	T061	C0039991
27623277	1601	1610	treatment	T061	C0087111
27623277	1614	1625	early-stage	T079	C2363430
27623277	1626	1652	non-small cell lung cancer	T191	C0007131
27623277	1654	1663	Treatment	T061	C0087111
27623277	1664	1672	modality	T077	C3889585
27623277	1677	1681	risk	T078	C0035647
27623277	1685	1702	cancer recurrence	T191	C0920420
27623277	1751	1760	treatment	T061	C0087111
27623277	1761	1772	preferences	T078	C0558295
27623277	1774	1782	Provider	T097	C0031831
27623277	1783	1793	experience	T041	C0596545
27623277	1819	1823	need	T169	C1514873
27623277	1827	1833	travel	T056	C0040802
27623277	1838	1849	lung cancer	T191	C0242379
27623277	1850	1859	treatment	T061	C0087111